737P Phase II study of IV vinorelbine in relapsed platinum resistant or refractory C5 high grade serous primary peritoneal, fallopian tube or ovarian cancer (VIP)

Natalie Yl Ngoi ,D Anne,K.T Kuay,J.Y Lee,K.W Tham,Azrina Tan ,Suresh Varma ,Tan Tz ,David Bowtell ,Tarek Meniawy ,Linda Mileshkin ,Ren‐Chang Huang ,Michael Friedlander ,Jason Yongsheng Chan ,Mei-Yan Pang ,George Au-Yeung ,Wen-Yee Chay ,Clare L Scott ,Wai Loong Wong ,David S.p Tan

doi:10.1016/j.annonc.2021.08.1179

737P Phase II study of IV vinorelbine in relapsed platinum resistant or refractory C5 high grade serous primary peritoneal, fallopian tube or ovarian cancer (VIP)

Natalie Yl Ngoi , D Anne + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.1179

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
License type: publisher-specific-oa

Affiliation: National University Cancer Institute, Singapore, KK Women's and Children's Hospital, National University of Singapore, Peter MacCallum Cancer Centre, Linear Clinical Research, National Taiwan University, Prince of Wales Hospital, National Cancer Centre Singapore, Walter and Eliza Hall Institute of Medical Research

#High-grade Serous Ovarian Cancer #Subtypes Of Ovarian Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The Australian Ovarian Cancer Study identified 4 distinct molecular subtypes of high-grade serous ovarian cancer (HGSOC). C5 subtype is linked to poor prognosis and stemness behavior. We have previously described dependency of C5 HGSOC on genes related to microtubule dynamics. In vitro and vivo studies have shown sensitivity of C5 subtype HGSOC cell lines and patient-derived xenografts to tubulin-depolymerizing vinca alkaloids such as vinorelbine.

Full Text